<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01218971</url>
  </required_header>
  <id_info>
    <org_study_id>ALK21-003-EXT</org_study_id>
    <nct_id>NCT01218971</nct_id>
  </id_info>
  <brief_title>ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of Medisorb® Naltrexone (VIVITROL®)</brief_title>
  <official_title>A Multicenter Double-Blind Extension of Alkermes Study ALK21-003 to Evaluate the Long-Term Safety of Medisorb® Naltrexone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alkermes, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alkermes, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a Phase 3 multicenter extension of Alkermes' Study ALK21-003 (NCT01218958 [the base
      study]) that evaluated the safety of Medisorb® naltrexone (VIVITROL®) administered every 4
      weeks for 48 weeks (13 injections) in alcohol-dependent adults who had completed Study
      ALK21-003.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All participants in this study received Medisorb naltrexone at double-blinded dose strengths
      (ie, 190 mg or 380 mg); no participant received placebo. Participants who had received
      Medisorb naltrexone in Study ALK21-003 (NCT01218958) continued to receive the same dose
      strength in this extension study. Those who had received placebo for Medisorb naltrexone 190
      mg in the base study were given Medisorb naltrexone 190 mg. Participants who had received
      placebo for Medisorb naltrexone 380 mg in the base study were given Medisorb naltrexone 380
      mg.

      Neither the identity or dose of the treatment received in the base study, nor the Medisorb
      naltrexone dose strength (190 mg or 380 mg) received in this extension were revealed to any
      participant, the investigator, or any blinded member of the clinical study team during the
      conduct of the base study or this extension.

      All participants were encouraged to receive standardized biopsychosocial support at each
      clinic visit throughout the study; however, unlike the base study, participation was not
      mandatory.

      Participants eligible for this extension study had received all 6 injections of study drug in
      the base study; those who received Medisorb naltrexone in the base study who also received
      all 13 injections in this extension therefore had a duration of exposure of approximately 76
      weeks (~1.5 years) upon completion of this extension. For participants who had received
      placebo in the base study, maximum duration of exposure was approx. 48 weeks (1 year).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <completion_date type="Actual">September 2004</completion_date>
  <primary_completion_date type="Actual">September 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While in Study</measure>
    <time_frame>Up to 48 weeks (13 injections), not including base study</time_frame>
    <description>A TEAE is any adverse event, whether or not considered drug-related, that develops or worsens in severity after study drug administration begins (ie, from the first administration through the end of the follow-up period).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">332</enrollment>
  <condition>Alcohol Dependence</condition>
  <arm_group>
    <arm_group_label>Medisorb naltrexone 380 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular (IM) injection administered once every 4 weeks for up to 48 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medisorb naltrexone 190 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IM injection administered once every 4 weeks for up to 48 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medisorb naltrexone 190 mg</intervention_name>
    <description>naltrexone for extended-release injectable suspension</description>
    <arm_group_label>Medisorb naltrexone 190 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medisorb naltrexone 380 mg</intervention_name>
    <description>naltrexone for extended-release injectable suspension</description>
    <arm_group_label>Medisorb naltrexone 380 mg</arm_group_label>
    <other_name>VIVITROL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Primary Inclusion Criteria:

          -  Completed study drug treatment in Study ALK21-003 (base study [NCT01218958])

          -  Written informed consent for this extension study

          -  Stable address and telephone; reconfirmation of contact's address and phone

          -  Women with childbearing potential must agree to continue to use an approved method of
             birth control throughout study participation

        Primary Exclusion Criteria:

          -  Positive urine drug screen for opioids at Visit 1

          -  Early termination of study drug in the base study

          -  Pregnancy or lactation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard L Silverman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alkermes, Inc.</affiliation>
  </overall_official>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2010</study_first_submitted>
  <study_first_submitted_qc>October 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 13, 2010</study_first_posted>
  <results_first_submitted>November 8, 2010</results_first_submitted>
  <results_first_submitted_qc>November 8, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 8, 2010</results_first_posted>
  <last_update_submitted>December 8, 2010</last_update_submitted>
  <last_update_submitted_qc>December 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Bernard Silverman, MD / Vice President, Clinical Development</name_title>
    <organization>Alkermes, Inc.</organization>
  </responsible_party>
  <keyword>Alcohol Dependence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcoholism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Medisorb Naltrexone 380 mg</title>
        </group>
        <group group_id="P2">
          <title>Medisorb Naltrexone 190 mg</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="175"/>
                <participants group_id="P2" count="157"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Medisorb Naltrexone 380 mg</title>
        </group>
        <group group_id="B2">
          <title>Medisorb Naltrexone 190 mg</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="175"/>
            <count group_id="B2" value="157"/>
            <count group_id="B3" value="332"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="149"/>
                    <measurement group_id="B3" value="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.5" spread="9.6"/>
                    <measurement group_id="B2" value="47.4" spread="10.5"/>
                    <measurement group_id="B3" value="46.4" spread="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="175"/>
                    <measurement group_id="B2" value="157"/>
                    <measurement group_id="B3" value="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While in Study</title>
        <description>A TEAE is any adverse event, whether or not considered drug-related, that develops or worsens in severity after study drug administration begins (ie, from the first administration through the end of the follow-up period).</description>
        <time_frame>Up to 48 weeks (13 injections), not including base study</time_frame>
        <population>All participants who received at least 1 dose of study drug are included in the safety population.</population>
        <group_list>
          <group group_id="O1">
            <title>Medisorb Naltrexone 380 mg</title>
          </group>
          <group group_id="O2">
            <title>Medisorb Naltrexone 190 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reporting at Least 1 Treatment-emergent Adverse Event (TEAE) While in Study</title>
          <description>A TEAE is any adverse event, whether or not considered drug-related, that develops or worsens in severity after study drug administration begins (ie, from the first administration through the end of the follow-up period).</description>
          <population>All participants who received at least 1 dose of study drug are included in the safety population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143"/>
                    <measurement group_id="O2" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year (Baseline to Week 52)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Medisorb Naltrexone 380mg--Combined</title>
          <description>Includes all participants who received Medisorb naltrexone 380mg in this extension study. Study drug was administered via intramuscular (IM) injection once every 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Medisorb Naltrexone 190mg--Combined</title>
          <description>Includes all participants who received Medisorb naltrexone 190mg in this extension study. Study drug was administered via intramuscular (IM) injection once every 4 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Placebo to 380mg</title>
          <description>Includes participants who received placebo in the base study but switched to Medisorb naltrexone 380mg in this extension. Study drug was administered via intramuscular (IM) injection once every 4 weeks.</description>
        </group>
        <group group_id="E4">
          <title>380mg to 380mg</title>
          <description>Includes participants who received Medisorb naltrexone 380mg in the base study and continued with the same dose strength in this extension. Study drug was administered via intramuscular (IM) injection once every 4 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Placebo to 190mg</title>
          <description>Includes participants who received placebo in the base study but switched to Medisorb naltrexone 190mg in this extension. Study drug was administered via intramuscular (IM) injection once every 4 weeks.</description>
        </group>
        <group group_id="E6">
          <title>190mg to 190mg</title>
          <description>includes participants who received Medisorb naltrexone 190mg in the base study and continued with the same dose strength in this extension. Study drug was administered via intramuscular (IM) injection once every 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (4.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Limb injury NOS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc degeneration NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Pancreatic carcinoma NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Drug abuser NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (4.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="143" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="130" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="92" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="46" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="84" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Vomiting NOS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Sinusitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Bronchitis NOS</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral NOS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Back injury NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Appetite decreased NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pain in limb</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache NOS</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Anxiety NEC</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash NOS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="175"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="157"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="60"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Should a PI wish to disclose results, the Sponsor will review the results communications prior to public release and can embargo results communications for a period of at least 30 days prior to the submission, for review and approval. Revisions will be negotiated in good faith by the Investigator and Sponsor and may be submitted for publication or disclosed by the Investigator only following receipt of written approval from the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bernard L. Silverman, MD</name_or_title>
      <organization>Alkermes, Inc.</organization>
      <phone>781-609-6000</phone>
      <email>bernard.silverman@alkermes.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

